More than one in 10 people with amyotrophic lateral sclerosis (ALS) harbor at least one known disease-causing mutation, according to a new profile from the Strategic ALS Australia Systems Genomics Consortium (SALSA-SGC). The multi-site research consortium brings together major ALS clinics across Australia to collect clinical data and biological…
News
A new wearable soft-glove device has successfully restored hand function in a man with amyotrophic lateral sclerosis (ALS), allowing him to grip objects and feed himself independently. The device was developed by a team of scientists in Germany who worked in direct collaboration with the patient himself. The man…
Neuralink, a company developing brain-computer interface (BCI) devices aimed at restoring independence to people with paralysis caused by conditions such as amyotrophic lateral sclerosis (ALS), has tested a new implant approach in which electrode threads were inserted through the dura without cutting it open. The dura is the…
A University of Melbourne spinout company is developing a less invasive brain-computer interface that could one day allow people with impaired speech, including those with amyotrophic lateral sclerosis (ALS), to communicate by attempting to say words. Unlike many current brain-computer interface prototypes, which can involve invasive surgery…
Incorporating muscle assessments from whole-body MRIs (WB-MRIs) into the diagnostic process for amyotrophic lateral sclerosis (ALS) may help identify the condition with a greater degree of certainty, according to a study from France. ALS causes damage to specialized nerve cells called motor neurons. Some criteria for diagnosing ALS…
Oral amyotrophic lateral sclerosis (ALS) treatment PrimeC significantly reduced levels of TDP-43, a protein that abnormally accumulates in nearly all ALS cases, in a Phase 2b clinical trial. The PARADIGM study met its main efficacy goal of lowering TDP-43 levels in nerve cells relative to a placebo after six months.
Former NFL running back Chris Johnson, whose historic 2,000 rushing yards in a season earned him the nickname CJ2K, has revealed that he is living with amyotrophic lateral sclerosis (ALS), saying he hopes sharing his story will encourage earlier diagnoses, inspire more research, and give hope to others facing…
Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…
The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide designed to target abnormalities in fat metabolism that may contribute to amyotrophic lateral sclerosis (ALS). The NeurALS trial (NCT07660614) is now recruiting an estimated 56 adults with ALS at…
Recent Posts
- ‘Unprecedented’ survival boost seen with new gene therapy in ALS model
- Blood protein panel may help forecast ALS symptom onset in gene carriers
- Study of veterans shows ALS risk varies by military branch, rank
- ALS-causing gene mutations disrupt key protein machinery: Study
- Higher levels of certain fat molecules in the body may increase ALS risk